According to a survey carried out in five European countries in 2020, almost 70 percent of women who were eligible for hormone therapy (HT) in Spain were adverse to taking the medication. Over a fifth of respondents in Germany said they were HT contraindicated which meant they were advised against using it due to certain conditions.
Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020
Expanded meanings:
- HT contraindicated: Issues such as vaginal bleeding, metastatic solid tumor, tumor without metastasis, angina pectoris, myocardial infarction, thrombosis. coagulated blood clotting disorder, liver disease.
- Caution required at HT initiation - Conditions requiring a cardiovascular or breast cancer evaluation before HT, current smoker, BMI overweight, family or personal history of breast cancer, history of migraine, diabetes, and elevated cholesterol/hyperlipidemia.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Elsevier. (June 23, 2022). Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020 [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/
Elsevier. "Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020." Chart. June 23, 2022. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/
Elsevier. (2022). Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/
Elsevier. "Feelings towards Receiving Hormone Therapy among Those with Vms Due to The Menopause in France, Germany, Italy, Spain, and The Uk as of 2020." Statista, Statista Inc., 23 Jun 2022, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/
Elsevier, Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020 Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/ (last visited November 10, 2024)
Feelings towards receiving hormone therapy among those with VMS due to the menopause in France, Germany, Italy, Spain, and the UK as of 2020 [Graph], Elsevier, June 23, 2022. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1366300/interest-in-taking-ht-for-menopause-in-europe/
